Oxaliplatin Novaplus 01
Oxaliplatin Injection, Solution
Product Images NDC 0781-9315
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 0781-9315). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Oxaliplatin Novaplus 02
The text describes a graph displaying DFS probability over time in months for patients receiving two different treatments, FOLFOX4 and LVSFU2. The graph includes the number of events and patients at risk for each treatment arm, as well as the hazard ratio and stratified logrank test results. At 60 months, the DFS probability for FOLFOX4 is approximately 0.2 and for LVSFU2 is approximately 0.3. The hazard ratio of FOLFOX4 compared to LVSFU2 is 0.80 with a 95% confidence interval of 0.68 to 0.93. The stratified logrank test yielded a p-value of 0.003.*
Oxaliplatin Novaplus 03
This is a graph showing DFS Probability at different time points (in months) for a treatment arm (FOLFOX4) and a control arm (LV5FU2) in patients with Dukes C colorectal cancer. The Hazard Ratio for stage III patients is 0.78 with a 95% confidence interval of [0.65, 0.93], and the Logrank test has a p-value of 0.005.*
Oxaliplatin Novaplus 04
This is a chart showing the percentage of patients surviving and median survival months based on three different treatments: Oxaliplatin + 5-FU/LV, Irinotecan + 5-FU/LV, and Irinotecan + 5-FU/LV. The chart shows that the Oxaliplatin + 5-FU/LV treatment had the highest percentage of patients surviving and the longest median survival time. A statistical test was done comparing Oxaliplatin +5-FU/LV to Irinotecan + 5-FU/LV with significant results.*
Oxaliplatin Novaplus 05
The text contains information about Oxaliplatin, an injectable medication used as a cytotoxic agent. It is available in single-dose vials containing 50mg/10mL concentration. The medication should be protected from light and not frozen. The packaging includes a caution regarding its use, and it is available only by prescription.*
Oxaliplatin Novaplus 06
This appears to be a label for a medication called Oxaliplatin Injection, USP, which is administered intravenously. The medication comes in single-dose vials, with a concentration of 100mg/20ml. There are multiple NDC codes listed for different quantities of the medication. The label also includes the name of the manufacturer and a mention of a company called Novaplus.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
